Credits: Canva
Until law, GLP-1 drugs were used to treat diabetes, obesity and even the recent evidences suggest that it could as well be used to treat chronic kidney problems. There is yet another research, published in JAMA Psychiatry on February 25, titled Once-Weekly Semaglutide in Adults With Alcohol Use Disorder: A Randomized Clinical Trial that explores if GLP-1 receptor agonist semaglutide reduce alcohol consumption and cravings in adults with alcohol use disorder.
The research was conducted over a period of 9 weeks, where in the randomized clinical trial, the participants who were administered semaglutide, it led to reductions in some but not all measures of weekly consumptions. It also reduced weekly alcohol and craving related to placebo, and also led to a greater relative reduction in cigarettes per day.
The research also found that weekly injections of semaglutide, which is the active ingredient in weight loss drugs like Wegovy also helped reduce cravings in people with alcohol use disorder.
The lead author Christian Hendershot said that these findings will help in developing new approaches to treat alcoholism. "Two drugs currently approved to reduce alcohol consumption aren't widely used. The popularity of Ozempic and other GLP-1 receptor agonists increases the chances of broad adoption of these treatments for alcohol use disorder," said Hendershot in news release by the University of Southern California's Institute for Addiction Research, where he is the director.
The study is government-funded research and was funded by the National Institute on Alcohol Abuse and Alcoholism, part of the National Institutes of Health.
The study was small, and took in account for only 48 adults over two months, thus experts say that it is not yet clear how safe these drugs are for people who do not need to lose weight. Though the results do add up with the evidence form animal studies on drugs like Ozempic and Wegovy on how it helps manage cravings, not just for food, but also for tobacco and alcohol. Scientists are also studying these drugs on smokers, people with opioid addiction and cocaine users.
Co-author Dr Klara Klein of the University of North Carolina at Chapel Hill who treats people with obesity and diabetes said, "This is such promising data. And we need more of it. We frequently will hear that once people start these medications that their desire to drink is very reduced, if not completely abolished."
The GLP-1 receptor agonists work by mimicking hormones GLP-1 in the gut and brain that regulates appetite and feelings of fullness. This response is what helps one lose weight, and what helps one curb their craving for alcohol. These drugs that mimic the functioning of your brain, which is responsible to tell your body when to stop consuming, are the same hormones that tell your body about other kinds of consumptions, including alcohol. Therefore by consuming the weight loss drugs one can treat alcohol use disorder.
However, the researchers have pointed out on the limited data on the research and have suggested to continue using the three approved drugs by the National Institute on Alcohol Abuse and Alcoholism and Substance Abuse and Mental Health Services Administration, namely, Disulfiram, Naltrexone, and Acamprosate to treat alcohol use disorder until large studies confirm these findings.
Credit: AI
Healthcare affordability was one of the major influencers of US midterm election outcomes. A recent poll revealed that more than half of US voters believe their healthcare costs have worsened under President Donald Trump's administration.
The analysis by health policy research organisation KFF was published a day after the 2026 midterm elections' results were announced. It found that 54% of midterm voters said the administration's policies had made their personal healthcare costs worse. Only 10% said their costs had improved.
Voters who said their healthcare costs had increased were more likely to support Democratic candidates. Among this group, 82% voted for Democratic candidates, compared to 16% who voted Republican.
The findings come as Democrats made significant gains in the November 3 midterms, winning control of both the House of Representatives as well as the Senate.
Also read: 2026 US Election Results: What Democrats’ Wins Mean For RFK Jr’s MAHA Movement And Vaccine Policy
KFF's analysis of the 2026 Voter Poll found that Democrats had a 19-percentage-point advantage over Republicans on healthcare.
When asked which party was better equipped to handle healthcare, 49% of voters chose Democrats, compared to 30% who chose GOP.
This shows a bigger jump from the 2024 presidential election, when Democratic presidential candidate Kamala Harris had a seven-point lead over Donald Trump on the same issue.
Democrats also held a narrow advantage on the economy as 43% of voters said that they trusted the party to handle it better, compared to 37% who chose Republicans. This marked a sharp reversal from 2024, when Trump had a 10-point advantage over Harris on the economy.
The healthcare advantage was also visible among independent voters. Among independents who said Trump's policies had made their healthcare costs worse, 69% voted for Democratic candidates for Congress.
Also read: US Midterms: Where Did Voters Support Abortion Rights And Where Did They Reject Them?
Healthcare costs had emerged as a significant concern even before voters went to the polls. A separate KFF Health Tracking Poll conducted between September 16 and 21 found that six in 10 voters were worried about affording healthcare. This included 25% who were very worried and 35% who were somewhat worried.
The poll also found that 47% of voters considered healthcare costs an extremely significant issue for candidates to discuss during the midterm campaign.
Democratic candidates repeatedly highlighted healthcare affordability, criticising Republicans over the expiration of enhanced Affordable Care Act (ACA) premium tax credits and reductions in Medicaid spending included in the 2025 reconciliation law.
The enhanced ACA tax credits had helped lower insurance premiums for people purchasing coverage through the marketplaces. Their expiration raised concerns about higher insurance costs for many enrollees.
Medicaid spending reductions also became a key point of debate because of their implications for people relying on the government-funded health insurance programme.
Democrats' victory gives the party control of both chambers of Congress, creating opportunities to analyse Trump administration's healthcare policies and push for changes in insurance affordability and Medicaid. It also gives them room to bring reforms in reproductive healthcare, vaccine policies, and gender-affirming care.
However, implementing major policy changes may be difficult while Trump remains president, especially if legislation faces a presidential veto.
Credit: AI
Pennsylvania recently announced that an unvaccinated individual tested positive for measles and died, becoming the sixth measles-associated death of 2026. The state's outbreak continues to expand as confirmed infections have now crossed 1,400 cases across 45 of its 67 counties.
The Pennsylvania Department of Health confirmed on November 4 that the resident was from Jefferson County. Officials did not release more details about the individual.
The latest death brings Pennsylvania's total to six this year. The state has recorded 1,467 confirmed measles cases across 45 counties, with 283 hospitalisations, according to its latest update.
The outbreak began in late April and has become one of the largest measles outbreaks in the United States in more than three decades.
Also read: New York Reports First Measles-Associated Death In 30 Years As Cases Continue To Rise
The six deaths confirmed by Pennsylvania health officials involved residents of three counties, in which three were from Lancaster County, two from Jefferson County and one from Mifflin County.
The state also addressed reports of a separate death involving a Franklin County resident in October. However, its investigation had not found evidence meeting the criteria to classify that death as measles-associated as of November 4.
Pennsylvania's definition requires a person to have clinical evidence of measles infection and a positive laboratory test, with death occurring within 30 days since symptom begins.
There is also a difference between state and federal death counts. Pennsylvania has confirmed six deaths, while the Centers for Disease Control and Prevention (CDC) has reported three measles-related deaths in its national tally as of October 29. The CDC is working on standard definition to ascertain how measles-associated deaths are classified across states.
Also read: US Midterm Elections 2026: Abortion, Medicaid, Measles And Healthcare Issues At Stake
Pennsylvania is at the centre of a wider resurgence of measles in the country. The CDC reported 4,852 confirmed measles cases in the US as of October 29, 2026. Of these, 96% were connected to outbreaks.
The state also saw a sharp increase in vaccination activity. Healthcare providers administered more than 61,000 measles, mumps and rubella (MMR) vaccine doses in October, more than twice the usual monthly number of approximately 25,000 doses.
Measles is a highly contagious viral infection that spreads through the air when an infected person coughs or sneezes. The virus can remain infectious in the air or on surfaces for up to two hours.
Initial symptoms include high fever, cough, runny nose and red, watery eyes. A rash usually develops several days later, beginning on the face and spreading down the body.
Although many people recover, measles can cause serious complications, including pneumonia and encephalitis, or inflammation of the brain. It can also weaken the immune system and increase vulnerability to other infections.
The MMR vaccine remains the most effective protection. Two doses are approximately 97% effective against measles.
Pennsylvania health officials recommend that people check their vaccination records and speak to a healthcare provider if they are unsure whether they have received the recommended doses.
Infants aged six to 11 months living in or travelling to areas with sustained measles transmission may also be advised to receive an early vaccine dose. This does not replace the two routine doses recommended later.
Credit: AP Photos
The “Make America Healthy Again” (MAHA) movement, led by Robert F. Kennedy Jr., played a key role in helping Donald Trump win the presidency in 2024. Two years later, it faces growing political opposition, with Democrats challenging the Trump administration’s healthcare policies and Kennedy’s approach to public health.
In a historic shift in the balance of power, the Democratic Party has won control of both the House of Representatives and the Senate in the 3 November 2026 midterm elections, delivering a major setback to Trump and the Republican Party. The results gives Democrats greater scope to scrutinise and reverse the administration’s healthcare agenda, including Medicaid funding, federal health agency budgets and vaccine policies.
However, their ability to reverse existing policies will be constrained by presidential veto powers and the 60 Senate votes generally needed to overcome a filibuster. The new Congress is expected to take office in January 2027.
More than 100 doctors, nurses and other healthcare professionals entered the 2026 US elections, in what was described as an unprecedented wave of candidates healthcare backgrounds.
Several Democratic candidates with healthcare and public health backgrounds secured major victories. These included:
Read More: US Midterms: Where Did Voters Support Abortion Rights And Where Did They Reject Them?
At the same time, several Republican candidates associated with healthcare and the MAHA movement also faced defeats. They included:
The MAHA movement, which promised to tackle chronic diseases and reform America's healthcare system, has faced criticism over Kennedy's approach to vaccines and public health. Changes to federal vaccine recommendations have become contentious amid a measles resurgence threatening the US' measles elimination status.
Pennsylvania reported 1,426 measles cases and five associated deaths as of October 30, 2026, its first measles fatalities in 35 years. The outbreak also triggered a public dispute between Kennedy and Governor Josh Shapiro over the deaths and claims about fetal tissue used in developing the MMR vaccine.
Beyond vaccines, MAHA's push to address ultra-processed foods, food additives and pesticides such as glyphosate has faced criticism over delays and concerns about corporate influence on food policy.
Autism has also emerged as a contentious issue. Trump's and Kennedy's September 2025 announcement on investigating possible autism causes, including a proposed link with acetaminophen use during pregnancy, and the CDC's July 2026 revision questioning the established scientific position on vaccines and autism drew criticism from health experts. Extensive evidence has found no causal link between vaccines and autism.
Looking ahead, Democratic lawmakers could use their control of Congress to scrutinise Kennedy's public health policies, demand scientific evidence behind federal health decisions and push for greater investment in vaccination and disease prevention programmes.
Trump's changes to childhood vaccination recommendations could become a focus of congressional scrutiny. In August 2026, he signed an executive order recommending separate MMR shots once individual vaccines become available and separate appointments for childhood vaccinations, where feasible.
Healthcare professionals have warned that additional injections and appointments could complicate vaccination for families and increase the risk of delayed or missed doses.
The administration has also moved away from the universal hepatitis B birth-dose recommendation. Under revised CDC guidance adopted in December 2025, parents of infants born to mothers who test negative can decide with healthcare providers whether to administer the vaccine at birth or begin the series later.
Democrats could hold hearings and investigate changes to CDC vaccine recommendations, the restructuring of its Advisory Committee on Immunization Practices (ACIP), and the removal of vaccine experts from advisory panels. They could also scrutinise staffing and funding changes at federal health agencies.
However, congressional oversight does not automatically allow Democrats to reverse executive decisions or remove Kennedy as HHS secretary. Their influence will depend on their ability to pass legislation, shape federal funding and secure support for changes to the administration's healthcare policies.
© $2026 Times Horizon Private Limited